Vimarsana
Biggest News Aggregation in the World

Page 6 - Scientific Presentations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scientific Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scientific Presentations Today - Breaking & Trending Today

Tonix Pharmaceuticals Announces Research Agreement with University of Maryland Baltimore to Study TNX-1500 for the Prevention of Rejection in Heart Xenograft Transplantation in Animals - Vimarsana News

Tonix Pharmaceuticals Announces Research Agreement with University of Maryland Baltimore to Study TNX-1500 for the Prevention of Rejection in Heart Xenograft Transplantation in Animals

Tonix Pharmaceuticals Holding Corp. , a clinical-stage biopharmaceutical company, today announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore ,... | February 2, 2023

Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum - Vimarsana News

Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum

EP262 potently inhibits MRGPRX2-mediated mast cell degranulation in multiple in vitro assays and in vivo using a proprietary humanized MRGPRX2 knock-in model Data supports evaluation of EP262

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD's The Liver Meeting 2022 Seite 1 - Vimarsana News

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD's The Liver Meeting 2022 Seite 1

04.11.2022 - ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos’ oral and poster ... Seite 1

Why is Tonix Pharmaceuticals Holding Corp. (TNXP) down -95.99% from the day 1 this year? - Vimarsana News

Why is Tonix Pharmaceuticals Holding Corp. (TNXP) down -95.99% from the day 1 this year?

For the readers interested in the stock health of Tonix Pharmaceuticals Holding Corp. (TNXP). It is currently valued at $0.91. When the transactions were called off in the previous session, Stock hit the highs of $0.992, after setting-off with the price of $0.9809. Company’s stock value dipped to

SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update

15.08.2022 - BREXAFEMME (ibrexafungerp tablets) prescriptions in Q2 2022 increased 29 percent over Q1 2022, generating net revenues of $1.3 million in Q2 2022, compared to $0.7 million in Q1. SCYNEXIS filed a supplemental New Drug Application (sNDA) to expand ...